SG11201910053YA - Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies - Google Patents
Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathiesInfo
- Publication number
- SG11201910053YA SG11201910053YA SG11201910053YA SG11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA SG 11201910053Y A SG11201910053Y A SG 11201910053YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- california
- pct
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102017000047189A IT201700047189A1 (it) | 2017-05-02 | 2017-05-02 | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie |
| PCT/IB2018/053047 WO2018203256A1 (en) | 2017-05-02 | 2018-05-02 | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910053YA true SG11201910053YA (en) | 2019-11-28 |
Family
ID=59746302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910053Y SG11201910053YA (en) | 2017-05-02 | 2018-05-02 | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11198682B2 (de) |
| EP (2) | EP3825310A1 (de) |
| JP (1) | JP2020518595A (de) |
| KR (1) | KR102632109B1 (de) |
| CN (2) | CN110799505B (de) |
| CA (1) | CA3062260A1 (de) |
| IT (1) | IT201700047189A1 (de) |
| SG (1) | SG11201910053YA (de) |
| WO (1) | WO2018203256A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11952366B2 (en) | 2017-05-02 | 2024-04-09 | Fondazione Istituto Italiano Di Tecnologia | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019407650B2 (en) * | 2018-12-17 | 2022-10-27 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
| MX2022003617A (es) * | 2019-10-02 | 2022-05-30 | Tolremo Therapeutics Ag | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. |
| WO2021159993A1 (en) * | 2020-02-14 | 2021-08-19 | Pharmablock Sciences (Nanjing) , Inc. | Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof |
| IL307402A (en) * | 2021-04-07 | 2023-12-01 | Tolremo Therapeutics Ag | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4105948B2 (ja) * | 2000-09-15 | 2008-06-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| PL377821A1 (pl) * | 2002-11-21 | 2006-02-20 | Chiron Corporation | 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| NZ588526A (en) * | 2008-05-23 | 2012-08-31 | Wyeth Llc | Triazine compounds as pi3 kinase and mtor inhibitors |
| JP2012529512A (ja) * | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| US9481670B2 (en) * | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| HRP20220913T1 (hr) * | 2012-10-05 | 2022-10-28 | Kadmon Corporation, Llc | Inhibitori rho kinaze |
| KR20160002850A (ko) * | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
| IT201700047189A1 (it) | 2017-05-02 | 2018-11-02 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie |
-
2017
- 2017-05-02 IT IT102017000047189A patent/IT201700047189A1/it unknown
-
2018
- 2018-05-02 KR KR1020197035653A patent/KR102632109B1/ko active IP Right Grant
- 2018-05-02 WO PCT/IB2018/053047 patent/WO2018203256A1/en unknown
- 2018-05-02 CN CN201880042801.0A patent/CN110799505B/zh active Active
- 2018-05-02 EP EP20217990.9A patent/EP3825310A1/de active Pending
- 2018-05-02 EP EP18723986.8A patent/EP3619202B1/de active Active
- 2018-05-02 SG SG11201910053Y patent/SG11201910053YA/en unknown
- 2018-05-02 US US16/609,720 patent/US11198682B2/en active Active
- 2018-05-02 CN CN202011176090.1A patent/CN112279833B/zh active Active
- 2018-05-02 JP JP2019559771A patent/JP2020518595A/ja active Pending
- 2018-05-02 CA CA3062260A patent/CA3062260A1/en active Pending
-
2021
- 2021-11-23 US US17/456,346 patent/US11952366B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11952366B2 (en) | 2017-05-02 | 2024-04-09 | Fondazione Istituto Italiano Di Tecnologia | Substituted 1,3,5-triazines as inhibitors for a rho family of GTP-ases |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3619202B1 (de) | 2021-06-30 |
| US11198682B2 (en) | 2021-12-14 |
| US11952366B2 (en) | 2024-04-09 |
| WO2018203256A1 (en) | 2018-11-08 |
| KR102632109B1 (ko) | 2024-01-31 |
| IT201700047189A1 (it) | 2018-11-02 |
| CA3062260A1 (en) | 2018-11-08 |
| CN110799505B (zh) | 2022-08-30 |
| CN110799505A (zh) | 2020-02-14 |
| KR20200015515A (ko) | 2020-02-12 |
| US20220242848A1 (en) | 2022-08-04 |
| EP3825310A1 (de) | 2021-05-26 |
| CN112279833B (zh) | 2024-04-16 |
| US20200062733A1 (en) | 2020-02-27 |
| EP3619202A1 (de) | 2020-03-11 |
| JP2020518595A (ja) | 2020-06-25 |
| CN112279833A (zh) | 2021-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910053YA (en) | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201809301YA (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201810318RA (en) | Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof |